For citations:
Karateev A.E., Pogozheva E.Yu., Amirjanova V.N., Filatova E.S., Lila A.M., Mazurov V.I., Samigullina R.R., Dadalova A.M., Dyo A.Yu., Chakieva D.S., Baranov A.A., Lapkina N.A., Koltsova E.N., Kiryukhina N.A., Shchendrigin I.N., Rasevich T.G., Davydova A.F., Semizarova I.V., Shafieva I.A., Bashkova I.B., Bobrikova D.A., Murtazalieva D.A., Kushnir I.N., Kalinina E.V., Salnikova T.S., Marusenko I.M., Semagina O.V., Vinogradova I.B., Krechikova D.G., Semchenkova M.Yu., Nasonov E.L. Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months. Rheumatology Science and Practice. 2021;59(4):394–400. (In Russ.) https://doi.org/10.47360/1995-4484-2021-394-400
Email this article 